ARTICLE | Company News

BiomX licenses new microbiome targets

January 30, 2018 1:00 PM UTC

Microbiome company BiomX Ltd. (Ness Ziona, Israel) said it exclusively sublicensed a set of new bacterial targets from JSR Corp. (Tokyo:4185) to develop and commercialize bacteriophage-based therapies for inflammatory bowel disease (IBD).

BiomX is using the licensed targets to develop lead candidate BX002, which it has been developing for over a year under a research deal with JSR. BiomX is customizing the phage cocktail to specifically target and eradicate bacteria from the gut that contribute to IBD. The company expects to submit an IND to FDA for BX002 in 2H19...